title: Development of a Patient-Derived Xenograft Model Using Brain Tumor Stem Cell Systems to Study Cancer.
abstract: Patient-derived xenograft (PDX) models provide an excellent platform to understand cancer initiation and development in vivo. In the context of brain tumor initiating cells (BTICs), PDX models allow for characterization of tumor formation, growth, and recurrence, in a clinically relevant in vivo system. Here, we detail procedures to harvest, culture, characterize, and orthotopically inject human BTICs derived from patient samples.
authors: McMaster Stem Cell and Cancer Research Institute, McMaster University, Hamilton, ON, Canada.
authors: Chirayu
authors: C
authors: Chokshi
authors: McMaster Stem Cell and Cancer Research Institute, McMaster University, Hamilton, ON, Canada.
authors: Manvir
authors: M
authors: Dhillon
authors: McMaster Stem Cell and Cancer Research Institute, McMaster University, Hamilton, ON, Canada.
authors: Nicole
authors: N
authors: McFarlane
authors: McMaster Stem Cell and Cancer Research Institute, McMaster University, Hamilton, ON, Canada.
authors: Chitra
authors: C
authors: Venugopal
authors: McMaster Stem Cell and Cancer Research Institute, McMaster University, Hamilton, ON, Canada. ssingh@mcmaster.ca.|Department of Biochemistry and Biomedical Sciences, Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada. ssingh@mcmaster.ca.|Department of Surgery, Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada. ssingh@mcmaster.ca.
authors: Sheila K
authors: SK
authors: Singh
mesh_terms: D000818:Animals; D015415:Biomarkers; D001932:Brain Neoplasms / Q000378:metabolism / Q000473:pathology*; D000066673:Cell Self Renewal; D004195:Disease Models, Animal; D005434:Flow Cytometry; D064593:Heterografts; D006801:Humans; D007150:Immunohistochemistry; D051379:Mice; D014411:Neoplastic Stem Cells / Q000378:metabolism / Q000473:pathology*; D018874:Spheroids, Cellular; D014407:Tumor Cells, Cultured; D014410:Tumor Stem Cell Assay
chemical_list: D015415:Biomarkers
keywords: Brain tumor-initiating cell (BTIC); Flow cytometry; Immunohistochemistry; In vitro proliferation assay; In vitro self-renewal assay; Intracranial injections; Lentivirus; NOD-SCID; Patient-derived xenograft (PDX)